Literature DB >> 21880586

Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation.

Yi-Bin Chen1, Jessica P Driscoll, Steven L McAfee, Thomas R Spitzer, Eric S Rosenberg, Rebecca Sanders, Ronald B Moss, Fang Fang, Francisco M Marty.   

Abstract

Parainfluenza virus (PIV) can cause significant morbidity after allogeneic stem cell transplantation (SCT). We report the first use of inhaled DAS181 for PIV in an allogeneic SCT recipient. Symptoms, oxygenation, and pulmonary function tests improved. Nasopharyngeal samples showed a reduction in viral load. DAS181 should be systematically evaluated for severe PIV infection.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21880586     DOI： 10.1093/cid/cir501

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  26 in total

1.  Characterizing the Cellular Immune Response to Parainfluenza Virus 3.

Authors:  Paibel I Aguayo-Hiraldo; Reuben J Arasaratnam; Ifigeneia Tzannou; Manik Kuvalekar; Premal Lulla; Swati Naik; Caridad A Martinez; Pedro A Piedra; Juan F Vera; Ann M Leen
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

Review 2.  Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.

Authors:  Roy F Chemaly; Dimpy P Shah; Michael J Boeckh
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

Review 3.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

4.  Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods.

Authors:  Sarah P Hammond; Lisa S Gagne; Shannon R Stock; Francisco M Marty; Rebecca S Gelman; Wayne A Marasco; Mark A Poritz; Lindsey R Baden
Journal:  J Clin Microbiol       Date:  2012-07-18       Impact factor: 5.948

5.  Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults.

Authors:  Jonathan M Zenilman; Edward J Fuchs; Craig W Hendrix; Christine Radebaugh; Robert Jurao; Seema U Nayak; Robert G Hamilton; J McLeod Griffiss
Journal:  Antiviral Res       Date:  2015-09-25       Impact factor: 5.970

6.  DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.

Authors:  S Chalkias; M R Mackenzie; C Gay; C Dooley; F M Marty; R B Moss; T Li; R L Routh; S R Walsh; C S Tan
Journal:  Transpl Infect Dis       Date:  2014-01-03       Impact factor: 2.228

7.  Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model.

Authors:  B G Jones; R T Hayden; J L Hurwitz
Journal:  Antiviral Res       Date:  2013-09-27       Impact factor: 5.970

8.  Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Authors:  Heba H Mostafa; Peter Vogel; Ashok Srinivasan; Charles J Russell
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 9.  Influenza prevention and treatment in transplant recipients and immunocompromised hosts.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

10.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.